Foot & Ankle Unit, Royal National Orthopaedic Hospital, Stanmore, United Kingdom.
Department of Orthopaedics & Musculoskeletal Science, University College London, London, United Kingdom.
Foot Ankle Int. 2024 Sep;45(9):943-949. doi: 10.1177/10711007241258159. Epub 2024 Jun 13.
Although the rate of venous thromboembolism (VTE) after foot and ankle surgery is low, multiple factors influence risk for individual patients. Furthermore, there are no clear guidelines on which patients may benefit from chemical thromboprophylaxis. Our aim was to assess patients not treated with chemical thromboprophylaxis after foot and ankle surgery, and to report on their specific patient and surgical risk factors for VTE.
This was a multicenter, prospective, national audit of patients undergoing foot and ankle surgery (including Achilles tendon ruptures) from 68 participating UK centers. The study was conducted between June 1, 2022, and November 30, 2022, with a further 3-month follow-up. Following data cleansing, 3309 patients were included who did not receive postoperative thromboprophylaxis.
Most patients were elective cases (2589 patients, 78.24%) with ASA grade I or II (2679 patients, 80.96%), fully weightbearing postoperatively (2752 patients, 83.17%), and either without ankle splintage, or splinted in a plantigrade boot (2797 patients, 84.53%). The VTE rate was 0.30% overall (11 cases), with no VTE-related mortality. No single demographic, surgical, or postoperative factor was associated with reduced risk of VTE. However, patients who had elective or trauma surgery not involving the ankle, who were ASA grade I or II and who were weightbearing immediately postoperatively (without splinting or in a plantigrade boot) had a VTE rate of 0.05% (1 of 1819 patients), compared with 0.67% (10 of 1490 patients, = .002).
Patients not receiving chemical thromboprophylaxis had a low incidence of symptomatic VTE, although they do represent a curated group considered lower risk. Within this group we describe characteristics associated with a substantially lower risk of VTE. All patients should be assessed on an individual basis, and further work is required to substantiate our findings.
尽管足部和踝关节手术后发生静脉血栓栓塞症(VTE)的风险较低,但多种因素会影响患者的个体风险。此外,对于哪些患者可能受益于化学血栓预防,目前尚无明确的指南。我们的目的是评估未接受足部和踝关节手术后化学血栓预防的患者,并报告他们的特定患者和手术 VTE 风险因素。
这是一项多中心、前瞻性、全国性的英国 68 家参与中心的足部和踝关节手术(包括跟腱断裂)患者的审计研究。该研究于 2022 年 6 月 1 日至 2022 年 11 月 30 日进行,并进行了 3 个月的随访。经过数据清理,共纳入 3309 例未接受术后血栓预防的患者。
大多数患者为择期手术(2589 例,78.24%),ASA 分级 I 或 II(2679 例,80.96%),术后完全负重(2752 例,83.17%),要么不使用踝关节夹板,要么使用足底承重靴(2797 例,84.53%)。总体 VTE 发生率为 0.30%(11 例),无 VTE 相关死亡。没有任何单一的人口统计学、手术或术后因素与 VTE 风险降低相关。然而,接受非踝关节手术的择期或创伤手术、ASA 分级 I 或 II 且术后立即负重(不使用夹板或使用足底承重靴)的患者,VTE 发生率为 0.05%(1819 例患者中的 1 例),而踝关节手术患者的 VTE 发生率为 0.67%(1490 例患者中的 10 例,=0.002)。
未接受化学血栓预防的患者发生症状性 VTE 的发生率较低,但他们确实代表了一个被认为风险较低的精选群体。在这个群体中,我们描述了与 VTE 风险显著降低相关的特征。所有患者都应进行个体化评估,需要进一步的工作来证实我们的发现。